Device Trial Radar · NCT06655740
Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Jun 30, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Aqua Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 23, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether RFVA of the duodenal mucosa with or without the combination of Semaglutide is a safe and effective treatment to remove the need for insulin therapy among patients with T2D who are on stable doses of insulin.
Conditions
- Diabetes Mellitus, Type 2
Interventions
RF Vapor AblationDevice
RF Vapor ablation of the duodenum
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EndpointTime frame: 1 month
- Efficacy EndpointTime frame: 168 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinica Colonial
Santiago, Chile
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.